

146.1307

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

JEAN-LUC DUBOIS

Serial No.: 09/202,217 Filed: December 9, 1998

For: NEW DEVICES...AS MEDICAMENTS

600 Third Avenue New York N.Y. 10016

DECLARATION

Asst. Commissioner for Patents Washington, D.C. 20231

Sir:

Jean-Claude Vieillefosse hereby deposes and says:

That he is head of the Patent Department of Aventis Pharma S.A. and was head of the Department during the time that Jean-Luc Dubois was employed by Aventis Pharma.

That as part of his duties, he reviews invention disclosures submitted by the researchers of Aventis Pharma to decide if the disclosure is patentable and if so, if it is of sufficient interest to justify filing a patent application.

That he received the invention disclosure for the present application submitted by Jean-Luc Dubois as a result of his research duties in accordance with his employment contract.

That he determined that the subject matter was patentable and of sufficient interest to justify filing a patent application.

That he therefor had the French priority application for the above application filed naming Jean-Luc Dubois as the inventor.

That the PCT application for the above application was timely designating, among others, the United States and then extended to

the United States without Jean-Luc Dubois' signature since when the application and assignment were submitted for signature, Jean-Luc Dubois refused to sign.

That he knows the above facts to be true from his own firsthand knowledge of the same.

It is declared by the undersigned that all statements made herein of undersigned's own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S. Code 1001, and that such willful false statements may jeopardize the validity of this application or any patent issuing thereon.

> aude Vieillefosse of Patent Dept. Aventis Pharma S.A.

Date: January 25, 2002

Jean-Claude VIEILLEFOSSE CHEF DU DÉPARTEMENT DES BREVETS FONDÉ DE POUVOIR

Aventis Pharma S.A.

Société Anonyme à Directoire et Conseil de Surveillance au Capital de 4 069 586 965 FRF 20, avenue Raymond Aron F - 92160 Antony

R.C.S. Nanterre B 304 463 284